Despite witnessing modest growth in demand over the past three months, Apellis Pharmaceuticals’ complement inhibitor for ...

Four months after Europe's Committee for Medicinal Products for Human Use (CHMP) rejected Apellis’ GA application for Syfovre for a second time, Astellas has withdrawn its application for the approval ...

Derek Archila has given his Hold rating due to a combination of factors concerning the market dynamics of Apellis Pharmaceuticals’s product Syfovre and its competition with Izervay. The survey ...

Astellas confirmed today that it will withdraw its EMA filing for avacincaptad pegol as a treatment for eye disorder ...

“Note there is a factor of two favoring Astellas’s chosen metric, given Izervay is monthly vs Syfovre’s majority use on the flexible EOM schedule,” Citi said. Citi added that Syfovre was ...

Thus, even though Syfovre has a competitive advantage over Izervay, William Blair believes both medications can thrive in light of the extensive market, significant unmet needs, and the absence of ...

Syfovre's brief position as the only GA treatment on the U.S. market didn't last long, however, as the FDA subsequently approved Izervay from rival Astellas Pharma. In the face of this competition ...

These injections deliver medication such as the new geographic atrophy drugs Syfovre (pegcetacoplan) and Izervay (avacincaptad pegol), powerful anti-VEGFs (vascular endothelial growth factor) to keep ...

Shares of Apellis Pharmaceuticals (NASDAQ: APLS) are down by about 62% from the peak they reached in January. However, ...

Mizuho lowered the firm’s price target on Apellis (APLS) to $38 from $39 and keeps a Neutral rating on the shares. The firm recently ...

Apellis Pharmaceuticals is marketing Syfovre, a new treatment for patients with a leading cause of blindness. Syfovre is approved in the U.S., but Apellis' stock tanked after European regulators ...